Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA4 | P22748 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 2/20 | 0.35 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30292812 | 1.00 | CA12 (0.35) | CA12CA1CA2CA4CA7 | |
| SCHEMBL26982160 | 0.81 | AHR (0.31) | — | |
| SCHEMBL26132679 | 0.80 | NPC1 (0.45) | ABCB1HTR1AGAAMAPTHPGD | |
| SCHEMBL30378734 | 0.80 | — | — | |
| SCHEMBL26132676 | 0.80 | — | — | |
| SCHEMBL19729164 | 0.80 | L3MBTL1 (0.42) | ACHEPTPN1HTR2AGAAKMT2A | |
| SCHEMBL31562652 | 0.79 | NPC1 (0.44) | ABCB1HTR1AGAAMAPTHPGD | |
| SCHEMBL30378277 | 0.79 | TDP1 (0.49) | HTR2AHTR1AGAAMAPTHPGD | |
| SCHEMBL26132406 | 0.79 | TDP1 (0.49) | HTR2AHTR1AGAAMAPTHPGD | |
| SCHEMBL9618610 | 0.77 | NPC1 (0.35) | SMN1; SMN2MEN1KMT2AKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115500357-B | Photosensitive bactericide based on berberine derivative | 深圳市儿童医院 | 2024-03-26 | — | — | CN | disclosed |
| CN-115500357-A | Photosensitive bactericide based on berberine derivative | 深圳市儿童医院 | 2022-12-23 | — | — | CN | disclosed |
| EP-1412327-A2 | INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE | LG Biomedical Institute (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030208067-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-11-06 | — | — | US | disclosed |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-10-02 | — | — | US | disclosed |
| WO-2002096867-A2 | INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE | LG BIOMEDICAL INSTITUTE (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208067-A1 | Inhibitors of protein kinase for the treatment of disease | MAP3K20, MAP3K1, MAP3K2 | CA12 4661/4885CA1 4632/4885CA2 2156/4885 |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | MAP3K20, MAP3K1, MAP3K2 | CA12 4661/4885CA1 4632/4885CA2 2156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.